|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,465.00 INR | +0.47% |
|
+0.09% | -6.05% |
| 06-11 | AstraZeneca Pharma India Gets India Approval to Use Enhertu in Breast Cancer Treatment | MT |
| 06-04 | Indian Equities End Marginally Higher on Thursday Ahead of Central Bank's Policy Decision | MT |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.81 | 5.31 | 10.1 | 10.39 | 10.34 | |||||
Return on Total Capital | 17.21 | 8.77 | 16.67 | 16.33 | 17.64 | |||||
Return On Equity % | 22.74 | 12.73 | 18.05 | 24.84 | 15.62 | |||||
Return on Common Equity | 22.74 | 12.73 | 18.05 | 24.84 | 15.62 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 63 | 60.66 | 63.51 | 53.63 | 43.55 | |||||
SG&A Margin | 27.03 | 28.58 | 25.83 | 18.67 | 15.09 | |||||
EBITDA Margin % | 16.3 | 10.26 | 16.09 | 14.14 | 14.48 | |||||
EBITA Margin % | 14.29 | 8.61 | 14.84 | 13.23 | 12.52 | |||||
EBIT Margin % | 14.29 | 8.61 | 14.84 | 13.23 | 12.52 | |||||
Income From Continuing Operations Margin % | 11.47 | 7.65 | 9.9 | 12.47 | 6.74 | |||||
Net Income Margin % | 11.47 | 7.65 | 9.9 | 12.47 | 6.74 | |||||
Net Avail. For Common Margin % | 11.47 | 7.65 | 9.9 | 12.47 | 6.74 | |||||
Normalized Net Income Margin | 9.63 | 6.22 | 10.71 | 9.86 | 9.22 | |||||
Levered Free Cash Flow Margin | 10.35 | 11.19 | 7.6 | -0.29 | 8.1 | |||||
Unlevered Free Cash Flow Margin | 10.43 | 11.26 | 7.64 | -0.24 | 8.16 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.1 | 0.99 | 1.09 | 1.26 | 1.32 | |||||
Fixed Assets Turnover | 9 | 9.97 | 13.66 | 19.19 | 26.73 | |||||
Receivables Turnover (Average Receivables) | 9.66 | 9.42 | 10.37 | 9.94 | 10.16 | |||||
Inventory Turnover (Average Inventory) | 1.85 | 2.11 | 2.22 | 2.87 | 2.5 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.04 | 2.12 | 2.18 | 2.61 | 1.91 | |||||
Quick Ratio | 1.46 | 1.64 | 1.61 | 1.89 | 1.05 | |||||
Operating Cash Flow to Current Liabilities | 0.35 | 0.3 | 0.15 | 0.08 | 0.09 | |||||
Days Sales Outstanding (Average Receivables) | 37.78 | 38.76 | 35.19 | 36.82 | 35.94 | |||||
Days Outstanding Inventory (Average Inventory) | 197 | 172.78 | 164.77 | 127.35 | 146.25 | |||||
Average Days Payable Outstanding | 239.54 | 224.92 | 183.53 | 121.64 | 92.4 | |||||
Cash Conversion Cycle (Average Days) | -4.76 | -13.39 | 16.43 | 42.53 | 89.8 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 2.66 | 1.69 | 1.22 | 0.64 | 4.64 | |||||
Total Debt / Total Capital | 2.59 | 1.66 | 1.21 | 0.64 | 4.43 | |||||
LT Debt/Equity | 1.89 | 0.98 | 0.63 | 0.39 | 3.82 | |||||
Long-Term Debt / Total Capital | 1.84 | 0.97 | 0.62 | 0.39 | 3.65 | |||||
Total Liabilities / Total Assets | 41.12 | 40.3 | 40.23 | 33.96 | 49.26 | |||||
EBIT / Interest Expense | 106.66 | 73.01 | 236.29 | 142.86 | 147.13 | |||||
EBITDA / Interest Expense | 124.78 | 90.85 | 262.1 | 155.2 | 173.53 | |||||
(EBITDA - Capex) / Interest Expense | 117.71 | 80.73 | 248.57 | 146.23 | 172.33 | |||||
Total Debt / EBITDA | 0.09 | 0.1 | 0.04 | 0.02 | 0.14 | |||||
Net Debt / EBITDA | -2.5 | -5.1 | -2.99 | -2.69 | -1.98 | |||||
Total Debt / (EBITDA - Capex) | 0.09 | 0.11 | 0.05 | 0.03 | 0.14 | |||||
Net Debt / (EBITDA - Capex) | -2.65 | -5.73 | -3.15 | -2.85 | -1.99 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -2.19 | -0.98 | 24.5 | 29.17 | 32.48 | |||||
Gross Profit, 1 Yr. Growth % | -1.47 | -4.65 | 30.34 | 9.07 | 7.59 | |||||
EBITDA, 1 Yr. Growth % | 12.41 | -37.66 | 95.15 | 13.52 | 35.65 | |||||
EBITA, 1 Yr. Growth % | 13.36 | -40.34 | 114.62 | 15.16 | 25.3 | |||||
EBIT, 1 Yr. Growth % | 13.36 | -40.34 | 114.62 | 15.16 | 25.3 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 29.21 | -33.98 | 61.18 | 62.66 | -28.34 | |||||
Net Income, 1 Yr. Growth % | 29.21 | -33.98 | 61.18 | 62.66 | -28.34 | |||||
Normalized Net Income, 1 Yr. Growth % | 10.22 | -35.98 | 114.21 | 18.9 | 23.97 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 29.21 | -33.98 | 61.18 | 62.66 | -28.34 | |||||
Accounts Receivable, 1 Yr. Growth % | 2.38 | 0.82 | 25.18 | 42.42 | 20.73 | |||||
Inventory, 1 Yr. Growth % | -3.24 | -12.25 | 35.65 | 19.8 | 140.7 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -11.27 | -9.76 | -8.48 | -7.62 | -1.94 | |||||
Total Assets, 1 Yr. Growth % | 9.68 | 10.57 | 14.98 | 9.46 | 40.82 | |||||
Tangible Book Value, 1 Yr. Growth % | 25.17 | 12.11 | 15.12 | 20.57 | 8.44 | |||||
Common Equity, 1 Yr. Growth % | 25.17 | 12.11 | 15.12 | 20.93 | 8.21 | |||||
Cash From Operations, 1 Yr. Growth % | 19.86 | -3.8 | -42.17 | -52.19 | 134.52 | |||||
Capital Expenditures, 1 Yr. Growth % | -45.78 | 24.77 | -11.43 | 26.29 | -83.74 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 10.42 | 7.05 | -15.4 | -104.98 | -3.76K | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 10.28 | 6.89 | -15.52 | -103.97 | -4.7K | |||||
Dividend Per Share, 1 Yr. Growth % | 100 | 400 | 60 | 50 | 33.33 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 5.69 | -1.59 | 11.03 | 26.81 | 30.81 | |||||
Gross Profit, 2 Yr. CAGR % | 2.22 | -3.07 | 11.48 | 19.23 | 8.33 | |||||
EBITDA, 2 Yr. CAGR % | 36.2 | -16.29 | 10.29 | 48.84 | 24.09 | |||||
EBITA, 2 Yr. CAGR % | 43.36 | -17.76 | 13.16 | 57.21 | 20.13 | |||||
EBIT, 2 Yr. CAGR % | 43.36 | -17.76 | 13.16 | 57.21 | 20.13 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 30.9 | -7.64 | 3.16 | 61.92 | 7.97 | |||||
Net Income, 2 Yr. CAGR % | 30.9 | -7.64 | 3.16 | 61.92 | 7.97 | |||||
Normalized Net Income, 2 Yr. CAGR % | 31.36 | -16 | 17.11 | 59.59 | 21.41 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 30.9 | -7.64 | 3.16 | 61.92 | 7.97 | |||||
Accounts Receivable, 2 Yr. CAGR % | 3.35 | 1.6 | 12.34 | 33.52 | 31.13 | |||||
Inventory, 2 Yr. CAGR % | 16.32 | -7.86 | 9.1 | 27.48 | 69.81 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 1.97 | -10.51 | -9.12 | -8.05 | -4.83 | |||||
Total Assets, 2 Yr. CAGR % | 17.43 | 10.12 | 12.75 | 12.19 | 24.15 | |||||
Tangible Book Value, 2 Yr. CAGR % | 23.15 | 18.46 | 13.6 | 17.81 | 14.34 | |||||
Common Equity, 2 Yr. CAGR % | 23.15 | 18.46 | 13.6 | 17.99 | 14.39 | |||||
Cash From Operations, 2 Yr. CAGR % | 38.05 | 7.38 | -25.41 | -47.42 | 5.89 | |||||
Capital Expenditures, 2 Yr. CAGR % | -35.77 | -17.75 | 5.12 | 5.76 | -54.68 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 31.96 | 8.72 | -4.84 | -79.48 | 35.05 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 32.5 | 8.57 | -4.98 | -81.68 | 35.15 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | 216.23 | 182.84 | 54.92 | 41.42 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 12.53 | 3.42 | 6.44 | 16.78 | 28.67 | |||||
Gross Profit, 3 Yr. CAGR % | 9.99 | -0.12 | 6.99 | 10.67 | 15.22 | |||||
EBITDA, 3 Yr. CAGR % | 39.1 | 4.96 | 10.99 | 11.36 | 44.31 | |||||
EBITA, 3 Yr. CAGR % | 49.87 | 7.03 | 13.22 | 13.82 | 45.76 | |||||
EBIT, 3 Yr. CAGR % | 49.87 | 7.03 | 13.22 | 13.82 | 45.76 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 53.28 | 4.2 | 11.2 | 20.07 | 23.4 | |||||
Net Income, 3 Yr. CAGR % | 53.28 | 4.2 | 11.2 | 20.07 | 23.4 | |||||
Normalized Net Income, 3 Yr. CAGR % | 39.63 | 3.38 | 14.77 | 17.7 | 46.71 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 53.28 | 4.2 | 11.2 | 20.07 | 23.4 | |||||
Accounts Receivable, 3 Yr. CAGR % | 15.96 | 2.5 | 8.92 | 21.59 | 29.12 | |||||
Inventory, 3 Yr. CAGR % | 12.2 | 5.89 | 4.82 | 12.56 | 57.56 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 2.45 | -2.1 | -9.84 | -8.62 | -6.06 | |||||
Total Assets, 3 Yr. CAGR % | 18.93 | 15.1 | 11.72 | 11.64 | 21.02 | |||||
Tangible Book Value, 3 Yr. CAGR % | 22.7 | 19.35 | 17.33 | 15.88 | 14.6 | |||||
Common Equity, 3 Yr. CAGR % | 22.7 | 19.35 | 17.33 | 15.99 | 14.63 | |||||
Cash From Operations, 3 Yr. CAGR % | 128.44 | 22.39 | -12.64 | -35.69 | -13.45 | |||||
Capital Expenditures, 3 Yr. CAGR % | 7.08 | -19.86 | -15.7 | 11.75 | -43.34 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 95.01 | 23.07 | -0 | -64.41 | 15.55 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 95.54 | 23.34 | -0.14 | -67.01 | 15.55 | |||||
Dividend Per Share, 3 Yr. CAGR % | - | - | 151.98 | 128.94 | 47.36 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 7.61 | 8.18 | 11.93 | 12.21 | 15.59 | |||||
Gross Profit, 5 Yr. CAGR % | 7.37 | 6.05 | 10.59 | 7.21 | 7.52 | |||||
EBITDA, 5 Yr. CAGR % | 50.46 | 12.13 | 26.77 | 20.7 | 16.06 | |||||
EBITA, 5 Yr. CAGR % | 248.02 | 17.62 | 33.93 | 24.82 | 15.94 | |||||
EBIT, 5 Yr. CAGR % | 248.02 | 17.62 | 33.93 | 24.82 | 15.94 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 77.74 | 25.17 | 30.82 | 24.29 | 9.89 | |||||
Net Income, 5 Yr. CAGR % | 77.74 | 25.17 | 30.82 | 24.29 | 9.89 | |||||
Normalized Net Income, 5 Yr. CAGR % | 85.39 | 16.66 | 30.14 | 22.99 | 17.38 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 77.74 | 25.17 | 30.82 | 24.29 | 9.89 | |||||
Accounts Receivable, 5 Yr. CAGR % | 0.49 | 14.84 | 14.5 | 13.94 | 17.31 | |||||
Inventory, 5 Yr. CAGR % | 15.37 | 19.43 | 10.95 | 14.05 | 27.13 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | -3.9 | -3.5 | -2.34 | -4.52 | -7.87 | |||||
Total Assets, 5 Yr. CAGR % | 13.96 | 15.57 | 16.42 | 13.92 | 16.53 | |||||
Tangible Book Value, 5 Yr. CAGR % | 23.93 | 18.07 | 18.98 | 18.73 | 16.13 | |||||
Common Equity, 5 Yr. CAGR % | 23.93 | 18.07 | 18.98 | 18.8 | 16.15 | |||||
Cash From Operations, 5 Yr. CAGR % | 12.95 | 21.48 | 45.99 | -12.71 | -5.65 | |||||
Capital Expenditures, 5 Yr. CAGR % | -3.14 | 11.23 | 6.29 | -10.46 | -34.23 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 21.79 | 17.44 | 46.36 | -39.88 | 12.77 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 21.99 | 17.59 | 46.51 | -42.47 | 12.71 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | - | - | - | 100 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















